Publication | Closed Access

A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers

UrologyOncologyAntisense InhibitorMedicineImmune Checkpoint InhibitorCastration-resistant Prostate CancerAnti-cancer AgentCancer TreatmentProstatic DiseasePharmacology